Claim verdict
GLP-1s
“Retatrutide produces more weight loss than currently approved GLP-1 medicines.”
This verdict applies to the exact claim above. It is not a verdict on the compound overall, a safety guarantee, or a recommendation to use it.
Registry verdict
Partly supported — the trial numbers are striking, but it isn't approved and long-term data are pending.
Why this verdict
- Randomised mid-stage human trials reported large dose-dependent weight reduction.
- Cross-trial comparisons are not head-to-head evidence; populations and protocols differ.
- Efficacy confidence is high; long-term safety confidence is not, because those data don't exist yet.